A combination of rhBMP-2 (recombinant human Bone Morphogenetic Protein-2) and MEK (MAP kinase/ERK kinase) inhibitor PD0325901 increases bone formation in a murine model of neurofibromatosis type I pseudarthrosis

Journal of Bone and Joint Surgery

Volumn 96, Issue 14, 2014, Pages

  El Hoss, J ^a   Cheng, T ^a   Carpenter, E C ^a   Sullivan, K ^a   Deo, N ^a   Mikulec, K ^a   Little, D G ^a   Schindeler, A ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BENZAMIDE DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; DIPHENYLAMINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METABOLISM; CALLUS; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FRACTURE HEALING; LOCAL THERAPY; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PSEUDARTHROSIS; SIGNAL TRANSDUCTION; TIBIA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; COMBINATION DRUG THERAPY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; NEUROFIBROMATOSIS TYPE 1;

ANIMALS; BENZAMIDES; BONE MORPHOGENETIC PROTEIN 2; DIPHENYLAMINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEUROFIBROMATOSIS 1; OSTEOGENESIS; PSEUDARTHROSIS; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84906306362     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.M.00862     Document Type: Article

References (39)

1. Hefti F, Bollini G, Dungl P, Fixsen J, Grill F, Ippolito E, Romanus B, Tudisco C, Wientroub S. Congenital pseudarthrosis of the tibia: history, etiology, classification, and epidemiologic data. J Pediatr Orthop B. 2000 Jan;9(1):11-5. (Pubitemid 30044014)
2. Vitale MG, Guha A, Skaggs DL. Orthopaedic manifestations of neurofibromatosis in children: an update. Clin Orthop Relat Res. 2002 Aug;401:107-18. (Pubitemid 34832841)
3. Anderson DJ, Schoenecker PL, Sheridan JJ, Rich MM. Use of an intramedullary rod for the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg Am. 1992 Feb;74(2):161-8.
4. Dobbs MB, Rich MM, Gordon JE, Szymanski DA, Schoenecker PL. Use of an intramedullary rod for treatment of congenital pseudarthrosis of the tibia. A long-term follow-up study. J Bone Joint Surg Am. 2004 Jun;86(6):1186-97. (Pubitemid 38724881)
5. Ghanem I, Damsin JP, Carlioz H. Ilizarov technique in the treatment of congenital pseudarthrosis of the tibia. J Pediatr Orthop. 1997 Sep-Oct;17(5):685-90. (Pubitemid 28048757)
6. Johnston CE, Birch JG. A tale of two tibias: a review of treatment options for congenital pseudarthrosis of the tibia. J Child Orthop. 2008 Mar;2(2):133-49. Epub 2008 Feb 21.
7. Johnston CE 2nd. Congenital pseudarthrosis of the tibia: results of technical variations in the Charnley-Williams procedure. J Bone Joint Surg Am. 2002 Oct;84(10):1799-810.
8. Ohnishi I, Sato W, Matsuyama J, Yajima H, Haga N, Kamegaya M, Minami A, Sato M, Yoshino S, Oki T, Nakamura K. Treatment of congenital pseudarthrosis of the tibia: a multicenter study in Japan. J Pediatr Orthop. 2005 Mar-Apr;25(2):219-24. (Pubitemid 40315442)
9. Paley D, Catagni M, Argnani F, Prevot J, Bell D, Armstrong P. Treatment of congenital pseudoarthrosis of the tibia using the Ilizarov technique. Clin Orthop Relat Res. 1992 Jul;280:81-93.
10. Plawecki S, Carpentier E, Lascombes P, Prevot J, Robb JE. Treatment of congenital pseudarthrosis of the tibia by the Ilizarov method. J Pediatr Orthop. 1990 Nov- Dec;10(6):786-90. (Pubitemid 20368672)
11. Richards BS, Oetgen ME, Johnston CE. The use of rhBMP-2 for the treatment of congenital pseudarthrosis of the tibia: a case series. J Bone Joint Surg Am. 2010 Jan;92(1):177-85.
12. Lee FY, Sinicropi SM, Lee FS, Vitale MG, Roye DP Jr, Choi IH. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. J Bone Joint Surg Am. 2006 Mar;88(3):627-33.
13. Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, D'Astous JL, Santora SD, Viskochil DH. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet. 2006 Jul;79(1):143-8. Epub 2006 May 10.
14. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF, Karsenty G. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 2006 Dec;4(6):441-51. (Pubitemid 44817348)
15. Kolanczyk M, Kühnisch J, Kossler N, Osswald M, Stumpp S, Thurisch B, Kornak U, Mundlos S. Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Med. 2008;6:21. Epub 2008 Jul 31.
16. Wang W, Nyman JS, Ono K, Stevenson DA, Yang X, Elefteriou F. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum Mol Genet. 2011 Oct 15;20(20):3910-24. Epub 2011 Jul 14.
17. Gutmann DH, Collins FS. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron. 1993 Mar;10(3):335-43. (Pubitemid 23111727)
18. El-Hoss J, Sullivan K, Cheng T, Yu NYC, Bobyn JD, Peacock L, Mikulec K, Baldock P, Alexander IE, Schindeler A, Little DG. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells. J Bone Miner Res. 2012 Jan;27(1):68-78.
19. Brown AP, Carlson TC, Loi CM, Graziano MJ. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol. 2007 Apr;59(5):671-9. Epub 2006 Aug 31.
20. Wang Y, Kim E, Wang X, Novitch BG, Yoshikawa K, Chang LS, Zhu Y. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell. 2012 Aug 17;150(4):816-30.
21. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013 Jan 2;123(1):340-7. Epub 2012 Dec 10.
22. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEKinhibition abrogatesmyeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013 Jan 2;123(1):335-9. Epub 2012 Dec 10.
23. Schindeler A, Little DG. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun. 2005 Dec 16;338(2):710-6. Epub 2005 Oct 11.
24. Zha YY, Shah R, Locke F, Wong A, Gajewski TF. Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb 29;331(1-2):94-102. Epub 2007 Dec 26.
25. Fouletier-Dilling CM, Bosch P, Davis AR, Shafer JA, Stice SL, Gugala Z, Gannon FH, Olmsted-Davis EA. Novel compound enables high-level adenovirus transduction in the absence of an adenovirus-specific receptor. Hum Gene Ther. 2005 Nov;16(11):1287-97. (Pubitemid 41611656)
26. Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ, Marth JD, Parada LF. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 2001 Apr 1;15(7):859-76. (Pubitemid 32295067)
27. Novak A, Guo C, Yang W, Nagy A, Lobe CG. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis. 2000 Nov-Dec;28(3-4):147-55.
28. Zhang L, Lee NJ, Nguyen AD, Enriquez RF, Riepler SJ, Stehrer B, Yulyaningsih E, Lin S, Shi YC, Baldock PA, Herzog H, Sainsbury A. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab. 2010 Jul;12(7):591-603.
29. Bonnet N, Bernard P, Beaupied H, Bizot JC, Trovero F, Courteix D, Benhamou CL. Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling. Toxicol Appl Pharmacol. 2007 May 15;221(1):111-8. Epub 2007 Feb 23.
30. Schindeler A, Ramachandran M, Godfrey C, Morse A, McDonald M, Mikulec K, Little DG. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. J Orthop Res. 2008 Jan;26(1):65-74.
31. Sharma R, Wu X, Rhodes SD, Chen S, He Y, Yuan J, Li J, Yang X, Li X, Jiang L, Kim ET, Stevenson DA, Viskochil D, Xu M, Yang FC. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. Hum Mol Genet. 2013 Dec 1;22(23):4818-28. Epub 2013 Jul 17.
32. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 2001 Jul 27;502(1-2):21-4. (Pubitemid 32722053)
33. El Khassawna T, Toben D, Kolanczyk M, Schmidt-Bleek K, Koennecke I, Schell H, Mundlos S, Duda GN. Deterioration of fracture healing in the mouse model of NF1 long bone dysplasia. Bone. 2012 Oct;51(4):651-60. Epub 2012 Jul 31.
34. Lee SM, Choi IH, Lee DY, Lee HR, Park MS, Yoo WJ, Chung CY, Cho TJ. Is double inactivation of the Nf1 gene responsible for the development of congenital pseudarthrosis of the tibia associated with NF1? J Orthop Res. 2012 Oct;30(10):1535-40. Epub 2012 Apr 05.
35. Sakamoto A, Yoshida T, Yamamoto H, Oda Y, Tsuneyoshi M, Iwamoto Y. Congenital pseudarthrosis of the tibia: analysis of the histology and the NF1 gene. J Orthop Sci. 2007 Jul;12(4):361-5. Epub 2007 Aug 02.
36. Cho TJ, Seo JB, Lee HR, Yoo WJ, Chung CY, Choi IH. Biologic characteristics of fibrous hamartoma from congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1. J Bone Joint Surg Am. 2008 Dec;90(12):2735-44.
37. Schindeler A, Birke O, Yu NYC, Morse A, Ruys A, Baldock PA, Little DG. Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate. J Bone Joint Surg Br. 2011 Aug;93(8):1134-9.
38. Birke O, Schindeler A, Ramachandran M, Cowell CT, Munns CF, Bellemore M, Little DG. Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia. J Child Orthop. 2010 Dec;4(6):507-17. Epub 2010 Oct 21.
39. Wang W, Nyman JS, Moss HE, Gutierrez G, Mundy GR, Yang X, Elefteriou F. Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J Bone Miner Res. 2010 Jul;25(7):1658-67.